The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...

Stem cells are often described as the body's master cells. Healthy stem cells can restore the blood system after cancer ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

CAR T-Cell Therapy Market SizeThe global CAR T-cell therapy market was worth USD 11.11 billion in 2024 and is expected to ...

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

The "Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global ...

and combinability with chemotherapy and other anti-lymphoma/-leukemia agents remain undefined. Preclinical ADCs for the Treatment of B-cell Malignancies Second-generation ADCs utilizing different ...